Adaptive Biotechnologies raises 2026 MRD revenue guide to $276M-$286M as it targets $1,700-$1,800 ASP (NASDAQ:ADPT)
Adaptive Biotechnologies (ADPT) raised its 2026 MRD revenue guidance to $276M-$286M, targeting $1,700-$1,800 ASP. The company reported Q3 profitability ahead of expectations, with continued MRD growth, according to CEO Chad Robins.
How this was made
The 30-second read
Why it matters
The guidance raise is likely to attract new buying pressure, especially from investors focused on high‑growth biotech.
Market read
The new guidance is material for ADPT shareholders and may influence related biotech stocks.
What to watch
Potential regulatory delays or competition could temper revenue growth.
Background
Adaptive Biotechnologies reported a breakthrough quarter, achieving company‑wide profitability and strong MRD revenue growth.
Ticker impact
Adaptive Biotechnologies raised its 2026 MRD revenue guidance to $276M-$286M.
upward pressure as investors price in higher revenue outlook
The new revenue range exceeds prior expectations and follows a profitability milestone, which typically drives buying interest.
Market effects
Boosts outlook for the broader immuno‑diagnostics sector as MRD adoption accelerates.
Positive for US biotech indices.
Limited to biotech investors; no broad market effect.
Counterpoint
If the guidance assumes optimistic reimbursement rates, the upside may be overstated.
Key entities
- CompanyAdaptive Biotechnologies
US‑listed biotech firm specializing in immune profiling.



